Dynavax Technologies Corp (DVAX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Eddie J. Gray
Employees:
249
2929 SEVENTH STREET, SUITE 100, BERKELEY, CA 94710
5108485100

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor biology to discover and develop novel vaccines and therapeutics. The company's development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company's other products under pipeline are SD-101, DV1179 Autoimmune Disease and AZD1419 Asthma Therapy. Dynavax Technologies was founded by Lawrence M. Lichtenstein, Dennis A. Carson and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Data derived from most recent annual or quarterly report
Market Cap 1.421 Billion Shares Outstanding119.952 Million Avg 30-day Volume 1.92 Million
P/E Ratio0.0 Dividend Yield0.0 EPS0.04
Price to Revenue9.3757 Debt to Equity1.8032 EBITDA-43.796 Million
Price to Book Value11.1806 Operating Margin-17.2569 Enterprise Value1.063 Billion
Current Ratio3.907 EPS Growth0.709 Quick Ratio2.894
1 Yr BETA 1.8455 52-week High/Low 21.39 / 5.87 Profit Margin-51.9085
Operating Cash Flow Growth74.7237 Altman Z-Score-1.3065 Free Cash Flow to Firm 540 Thousand
View SEC Filings from DVAX instead.

View recent insider trading info

Funds Holding DVAX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding DVAX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SUN ELAINE D

  • Director
55,714 2021-12-10 2

JANSSEN ROBERT SENIOR VICE PRESIDENT

  • Officer
97,373 2021-11-16 8

NOVACK DAVID F PRESIDENT & COO

  • Officer
44,066 2021-11-01 8

MYERS SCOTT DUNSETH

  • Director
0 2021-10-19 2

BURGESS JUSTIN PRINCIPAL ACCOUNTING OFFICER

  • Officer
3,721 2021-09-01 5

HACK ANDREW A. F.

  • Director
8,415,000 2021-08-27 4

CANO FRANCIS

  • Director
20,834 2021-08-24 2

PHILLIPS PEGGY V

  • Director
27,733 2021-08-23 2

KISNER DANIEL L

  • Director
25,000 2021-05-28 1

RICCIARDI NATALE S

  • Director
25,000 2021-05-28 1

EASTLAND JULIA MARIE

  • Director
25,000 2021-05-28 1

MACGREGOR BRENT

  • Director
25,000 2021-05-28 1

PARADISO PETER R.

  • Director
18,750 2021-05-28 1

MACDONALD KELLY SVP AND CFO

  • Officer
0 2021-03-01 2

SPENCER RYAN CEO AND DIRECTOR

  • Officer
  • Director
90,453 2021-02-22 2

OSTRACH MICHAEL S SENIOR VICE PRESIDENT

  • Officer
0 2021-02-03 1

ORONSKY ARNOLD L

  • Director
0 2020-05-28 0

JOHNSON DAVID LOUIS VICE PRESIDENT

  • Officer
48,380 2020-03-13 0

COFFMAN ROBERT SENIOR VICE PRESIDENT

  • Officer
77,768 2019-06-02 0

GRAY EDDIE CEO AND DIRECTOR

  • Officer
  • Director
304,597 2019-06-02 0

CARSON DENNIS

  • Director
0 2019-05-30 0

BREGE LAURA

  • Director
0 2019-05-30 0

PLOTKIN STANLEY A

  • Director
0 2017-06-02 0

GILBERT DENISE

  • Director
0 2014-05-28 0

DINA DINO

  • Director
0 2014-05-28 0

TUCK STEPHEN F VP, GLOBAL TECHNICAL OPS

  • Officer
0 2013-02-05 0

LEW JENNIFER VP, FINANCE & PAO

  • Officer
0 2013-02-05 0

MARTIN J TYLER PRESIDENT, CMO & DIRECTOR

  • Officer
  • Director
222,089 2012-11-16 0

KESSEL MARK

  • Director
3,031,431 2012-10-16 0

LARSON CHRISTINE R VP AND CHIEF FINANCIAL OFFICER

  • Officer
0 2012-08-13 0

JANOWICZ ZBIGNIEW CEO DYNAVAX EUROPE

  • Officer
0 2012-03-09 0

LAWRENCE DAVID M

  • Director
0 2010-05-12 0

BUC NANCY L

  • Director
0 2010-05-12 0

SYMPHONY CAPITAL PARTNERS LP

SYMPHONY CAPITAL GP, L.P.

SYMPHONY GP, LLC

SYMPHONY STRATEGIC PARTNERS LLC

TARANTO HARRI V

  • Director
  • 10% Owner
  • SEE FOOTNOTE 5 AND REMARKSSEE FOOTNOTE 5 AND REMARKSSEE FOOTNOTE 5 AND REMARKSSEE FOOTNOTE 5 AND REMARKSSEE FOOTNOTE 5 AND REMARKS
9,031,431 2010-04-16 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

LAMPERT MARK N

BVF INC/IL

  • 10% Owner
  • DIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNER
17,115,404 2009-09-10 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
25,254,628 2009-06-03 0

SMELTZER DEBORAH A VP, OPERATIONS & CFO

  • Officer
0 2009-03-10 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MANAGEMENT CO /NY

DEERFIELD SPECIAL SITUATIONS FUND INTERNATIONAL LTD

DEERFIELD PRIVATE DESIGAN FUND L P

DEERFIELD PRIVATE DESIGN INTERNATIONAL, L.P.

  • 10% Owner
No longer subject to file 2008-10-22 0

SANDERS MARTIN E EVP AND CDO

  • Officer
0 2008-10-03 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SUN ELAINE D - Director

2021-12-14 19:23:31 -0500 2021-12-10 A 10,714 a 10,714 direct

SUN ELAINE D - Director

2021-12-14 19:23:31 -0500 2021-12-10 A 45,000 a 45,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund DVAX -85562.0 shares, $-1665036.52 2021-08-31 N-PORT
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund DVAX -1753.0 shares, $-33675.13 2021-09-30 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund DVAX -113648.0 shares, $-2183178.08 2021-09-30 N-PORT
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio DVAX -33983.0 shares, $-652813.43 2021-09-30 N-PORT
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund DVAX -10882.0 shares, $-217313.54 2021-10-31 N-PORT

Elevate your investments